215 ILCS 200/77: Prior authorization for drug therapies for hereditary bleeding disorders.

Notwithstanding any other provision of law, a health insurance issuer or a contracted utilization review organization may not require a prior authorization for drug therapies approved by the U.S. Food and Drug Administration for the treatment of hereditary bleeding disorders more frequently than every 6 months or the length of time the prescription for that dosage remains valid, whichever period is shorter.